Bedrijfsoverzicht
Stevanato Group S.p.A. is a prominent entity within the healthcare sector, specifically operating in the medical instruments and supplies industry by designing, producing, and distributing specialized processes and products for the biopharma and healthcare markets across Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company's operational scale is substantial, evidenced by a market capitalization of $3.69B and an annual revenue of $1.19B, supported by a workforce of 6010 employees. These financial figures indicate that Stevanato Group S.p.A. maintains a significant position within its niche, serving as a critical infrastructure provider for the global biopharmaceutical supply chain rather than acting as a direct consumer of healthcare services. The breadth of its geographic footprint combined with its high employee count suggests a mature business model capable of sustaining operations across diverse international regulatory environments, which is essential for medical instrument manufacturers serving the biopharma industry.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $1.19B with a corresponding net income of $139.84M and an EBITDA of $283.56M, revealing a cost structure where operating expenses and taxes consume approximately 50% of gross earnings before interest and taxes. Free cash flow for the period stands at $-45,059,624, indicating a current period of cash burn that reflects significant capital expenditures likely required for manufacturing capacity expansion or facility upgrades in the medical instrument sector. The firm maintains a gross margin of 29.2%, an operating margin of 20.9%, and a profit margin of 11.8%, where the gap between operating and profit margins highlights the impact of interest expenses and income taxes on final profitability. In terms of leverage, the company holds $132.38M in cash against $469.70M in debt, resulting in a debt-to-equity ratio of 31.60, which suggests a balance sheet that is moderately leveraged and relies on external financing for operations. Short-term liquidity appears robust with a current ratio of 1.76, indicating sufficient current assets to cover short-term obligations without immediate distress. Management effectiveness is quantified by a return on equity of 9.7% and a return on assets of 5.2%, metrics that demonstrate the ability to generate returns on shareholder capital and total assets, though the ROA remains modest relative to the leverage applied.
Waarderingsbeoordeling
Valuation metrics for Stevanato Group S.p.A. show a trailing P/E ratio of 22.92 and a forward P/E of 15.82, implying that the market expects earnings to grow significantly in the coming years to justify the lower forward multiple compared to historical performance. The price-to-book ratio is 2.15, suggesting that the stock trades at a premium to its book value, which is typical for companies in the medical instruments industry where intangible assets and intellectual property contribute significantly to enterprise value. Alternative valuation measures include a price-to-sales ratio of 3.11 and an EV/EBITDA of 14.21, providing a more comprehensive view of value that accounts for debt and cash positions while normalizing earnings power relative to revenue generation. Price momentum is assessed within a 52-week range defined by a high of $28.00 and a low of $12.89, where the current valuation context must be interpreted against this volatility band to understand recent market sentiment shifts. The stock exhibits a beta of 0.62, indicating that its price volatility is approximately 38% lower than the broader market, which offers stability characteristics often sought by investors in defensive healthcare sectors.
Growth & Income
Revenue growth for the trailing twelve months is recorded at 4.8%, while earnings growth is significantly lower at 0.3%, indicating that the company's profitability is currently expanding at a much slower pace than its top-line sales expansion. This divergence suggests that recent revenue increases are not yet translating into proportional earnings growth, potentially due to the aforementioned negative free cash flow or one-time costs impacting the bottom line. As a dividend payer, the company offers a yield of 0.5% with a payout ratio of 10.6%, a conservative payout level that is highly sustainable given the low payout percentage relative to earnings and the substantial cash reserves available. The low dividend yield coupled with the minimal payout ratio reflects a strategy where the company prioritizes reinvesting earnings into operational growth and capacity building rather than returning maximum cash to shareholders. Overall, the growth and income profile presents a scenario of steady revenue expansion with lagging earnings growth and a modest, sustainable income stream designed for capital preservation.